Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

13.2%

7 terminated/withdrawn out of 53 trials

Success Rate

86.5%

+0.0% vs industry average

Late-Stage Pipeline

21%

11 trials in Phase 3/4

Results Transparency

64%

29 of 45 completed trials have results

Key Signals

29 with results7 terminated

Enrollment Performance

Analytics

Phase 1
21(46.7%)
Phase 2
13(28.9%)
Phase 3
10(22.2%)
Phase 4
1(2.2%)
45Total
Phase 1(21)
Phase 2(13)
Phase 3(10)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials
NCT03373383Phase 2Completed

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Role: lead

NCT03531008Completed

Human Epilepsy Project 2: Resistant Focal Seizures Study

Role: collaborator

NCT03861481Phase 2Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Role: lead

NCT02582866Phase 3Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Role: lead

NCT02963506Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Role: lead

NCT02969525Phase 2Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Role: lead

NCT01529034Phase 3Terminated

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Role: lead

NCT02905006Phase 2Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Role: lead

NCT03405714Phase 2Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

Role: lead

NCT03051217Phase 2Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Role: lead

NCT02890134Completed

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort

Role: collaborator

NCT03859219Phase 1Completed

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

Role: lead

NCT02687711Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

Role: lead

NCT03052751Phase 2Completed

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Role: lead

NCT04136444Phase 1Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Role: lead

NCT02346240Phase 3Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Role: lead

NCT03480243Phase 1Completed

Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil

Role: lead

NCT04075409Phase 1Completed

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Role: lead

NCT02804763Phase 2Completed

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Role: lead

NCT04013191Phase 1Completed

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

Role: lead